Loopbaan van Andreas Muhs
Eerdere bekende functies van Andreas Muhs
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| AC IMMUNE SA | Hoofd Techniek/Wetenschap/O&O | 01-01-2005 | 22-10-2018 |
Cardion GmbH
 Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Corporate Officer/Principal | - | - |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Opleiding van Andreas Muhs
| Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Statistieken
Internationaal
| Duitsland | 3 |
| Zwitserland | 2 |
| Verenigde Staten | 2 |
Operationeel
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
- Beurs
- Insiders
- Andreas Muhs
- Ervaring
